BR9814087A - Processos para mediar a atividade do receptor de ppar-gama, e para tratar uma condição fisiológica em um paciente - Google Patents

Processos para mediar a atividade do receptor de ppar-gama, e para tratar uma condição fisiológica em um paciente

Info

Publication number
BR9814087A
BR9814087A BR9814087-6A BR9814087A BR9814087A BR 9814087 A BR9814087 A BR 9814087A BR 9814087 A BR9814087 A BR 9814087A BR 9814087 A BR9814087 A BR 9814087A
Authority
BR
Brazil
Prior art keywords
ppar
mediate
treat
patient
processes
Prior art date
Application number
BR9814087-6A
Other languages
English (en)
Inventor
Zaid Jayyosi
Gerard M Mcgeehan
Michael F Kelley
Original Assignee
Aventis Pharm Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharm Prod Inc filed Critical Aventis Pharm Prod Inc
Publication of BR9814087A publication Critical patent/BR9814087A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"PROCESSOS PARA MEDIAR A ATIVIDADE DO RECEPTOR DE PPAR-GAMA, E PARA TRATAR UMA CONDIçãO FISIOLóGICA EM UM PACIENTE" Um processo para mediar a atividade do receptor de PPAR-<sym> compreende o dito receptor de PPAR-<sym> com um composto da fórmula (I) em que: A é O, S, ou uma ligação química; B é O, S, SO, SO~ 2~, NR~ 1~, uma ligação química; D é O, S, NR~ 1~, (1),ou uma ligação química; E é uma ligação química; a é de 0 a 2; b é 0 ou 1; c é de 0 a 4; d é de 0 a 5; e é de 0 a 4; f é de 0 a 5; n é de 0 a 2; R é independentemente hidrogênio; R' é independentemente hidrogênio; R~ 1~ é independentemente hidrogênio; R~ 2~ é -(CH~ 2~)~ q~-X ou dois R~ 2~ vicinais quando juntos com os átomos de carbono através dos quais os dois R~ 2~ vicinais estão ligados formam cicloalquileno ou o R~ 1~ e o R~ 2~ geminais, quando juntos; q é de 0 a 3; X é hidrogênio.
BR9814087-6A 1997-10-17 1998-10-16 Processos para mediar a atividade do receptor de ppar-gama, e para tratar uma condição fisiológica em um paciente BR9814087A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6231897P 1997-10-17 1997-10-17
US6590297P 1997-11-17 1997-11-17
PCT/US1998/021947 WO1999020275A1 (en) 1997-10-17 1998-10-16 Therapeutic uses of quinoline derivatives

Publications (1)

Publication Number Publication Date
BR9814087A true BR9814087A (pt) 2000-10-03

Family

ID=26742119

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9814087-6A BR9814087A (pt) 1997-10-17 1998-10-16 Processos para mediar a atividade do receptor de ppar-gama, e para tratar uma condição fisiológica em um paciente

Country Status (17)

Country Link
US (1) US6376512B1 (pt)
EP (1) EP1030665A4 (pt)
JP (1) JP2001520193A (pt)
KR (1) KR20010024533A (pt)
CN (1) CN1302206A (pt)
AP (1) AP2000001786A0 (pt)
AU (1) AU9696198A (pt)
BG (1) BG104432A (pt)
BR (1) BR9814087A (pt)
CA (1) CA2306825A1 (pt)
EA (1) EA200000427A1 (pt)
HU (1) HUP0101022A1 (pt)
IL (1) IL135673A0 (pt)
NO (2) NO20001962L (pt)
OA (1) OA11371A (pt)
PL (1) PL344977A1 (pt)
WO (1) WO1999020275A1 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1177187B1 (en) 1999-04-28 2007-07-25 Sanofi-Aventis Deutschland GmbH Di-aryl acid derivatives as ppar receptor ligands
JP2002543065A (ja) * 1999-04-28 2002-12-17 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｐｐａｐ受容体リガンドとしてのトリアリール酸誘導体
US7041691B1 (en) * 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
JP2003508389A (ja) 1999-08-27 2003-03-04 エリ リリー アンド カンパニー ビアリール−オキサ（チア）ゾール誘導体およびそのｐｐａｒモジュレーターとしての使用
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
TWI262185B (en) * 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
JP2001261654A (ja) * 2000-03-21 2001-09-26 Mitsui Chemicals Inc キノリン誘導体およびそれを有効成分として含有する核内レセプター作動薬
US6653332B2 (en) * 2000-05-03 2003-11-25 Tularik Inc. Combination therapeutic compositions and method of use
US20030171399A1 (en) * 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US7238716B2 (en) 2000-12-28 2007-07-03 Takeda Pharmaceuticals Company Limited Alkanoic acid derivatives process for their production and use thereof
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
TWI311133B (en) 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
HU230352B1 (hu) 2001-06-12 2016-02-29 Wellstat Therapeutics Corporation Metabolikus rendellenességek kezelésére adható vegyületek és ezeket tartalmazó gyógyászati készítmények
US7371777B2 (en) 2001-08-17 2008-05-13 Eisai Co., Ltd. Cyclic compound and PPAR agonist
ATE386013T1 (de) 2002-06-20 2008-03-15 Astrazeneca Ab Ortho-substituierte benzoesäurederivate zur behandlung von insulinresistenz
SE0201937D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
PL374860A1 (en) 2002-07-09 2005-11-14 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
EP1664002A1 (en) 2003-09-17 2006-06-07 Novartis AG Organic compounds
ATE486055T1 (de) 2004-05-05 2010-11-15 High Point Pharmaceuticals Llc Neue verbindungen, ihre herstellung und verwendung
JP4981662B2 (ja) 2004-05-05 2012-07-25 ハイ・ポイント・ファーマスーティカルズ、エルエルシー 新規の化合物、その製法と使用
CN100418532C (zh) * 2005-06-17 2008-09-17 吕志民 治疗多种疾病的NF-κB化合物抑制剂
RU2412935C2 (ru) 2005-06-30 2011-02-27 Хай Пойнт Фармасьютикалс, ЛЛС Феноксиуксусные кислоты в качестве активаторов дельта рецепторов ppar
AU2006287521A1 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. PPARactive compounds
EP2386540A1 (en) 2005-12-22 2011-11-16 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
WO2007101864A2 (en) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Compounds that modulate ppar activity, their preparation and use
US9308198B2 (en) 2006-09-08 2016-04-12 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced brain disease
US7645616B2 (en) * 2006-10-20 2010-01-12 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
RU2522458C2 (ru) * 2008-04-30 2014-07-10 Веллстат Терапьютикс Корпорейшн Тетразольные соединения для снижения концентрации мочевой кислоты
BRPI1011318A2 (pt) 2009-06-09 2019-09-24 California Capital Equity Llc derivados de triazina e suas aplicações terapêuticas
CA2765044A1 (en) 2009-06-09 2010-12-16 California Capital Equity, Llc Benzyl substituted triazine derivatives and their therapeutical applications
WO2010144586A1 (en) 2009-06-09 2010-12-16 Abraxis Bioscience, Llc Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling
ES2533065T3 (es) 2010-07-09 2015-04-07 Pfizer Limited Bencenosulfonamidas útiles como inhibidores de los canales de sodio
CA2801032A1 (en) 2010-07-12 2012-01-19 Pfizer Limited N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
JP2013531030A (ja) 2010-07-12 2013-08-01 ファイザー・リミテッド 電位開口型ナトリウムチャネルの阻害剤としてのｎ−スルホニルベンズアミド
CA2804716A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
CA2804877A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
US8772343B2 (en) 2010-07-12 2014-07-08 Pfizer Limited Chemical compounds
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US10099993B2 (en) * 2014-04-06 2018-10-16 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor positive allosteric modulators (PAMS) and uses thereof
CN116323560A (zh) * 2020-08-04 2023-06-23 精密生物治疗有限责任公司 作为胆汁酸受体和白三烯半胱氨酰受体的选择性和/或双重调节剂的喹啉化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
US4920132A (en) * 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US4920130A (en) * 1987-11-02 1990-04-24 Rorer Pharamceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
ATE177083T1 (de) * 1993-11-29 1999-03-15 Merrell Pharma Inc Benzolsulfonyliminderivate als inhibitoren der il-1 wirkung
EP0709377B1 (en) * 1994-10-27 1999-09-29 Asahi Glass Company Ltd. Process for producing quinolin-2-yl benzoic acid compounds
DK0871439T3 (da) * 1996-01-02 2004-08-02 Aventis Pharma Inc Substituerede (aryl, heteroaryl, arylmethyl eller heteroarylmethyl) hydroxamsyreforbindelser

Also Published As

Publication number Publication date
CA2306825A1 (en) 1999-04-29
NO20003107D0 (no) 2000-06-16
US6376512B1 (en) 2002-04-23
IL135673A0 (en) 2001-05-20
EP1030665A1 (en) 2000-08-30
BG104432A (bg) 2000-12-29
AP2000001786A0 (en) 2000-04-16
PL344977A1 (en) 2001-11-19
EA200000427A1 (ru) 2001-02-26
AU9696198A (en) 1999-05-10
OA11371A (en) 2004-01-28
KR20010024533A (ko) 2001-03-26
NO20001962L (no) 2000-06-16
NO20003107L (no) 2000-07-26
EP1030665A4 (en) 2002-11-27
JP2001520193A (ja) 2001-10-30
WO1999020275A1 (en) 1999-04-29
NO20001962D0 (no) 2000-04-14
HUP0101022A1 (hu) 2001-10-28
CN1302206A (zh) 2001-07-04

Similar Documents

Publication Publication Date Title
BR9814087A (pt) Processos para mediar a atividade do receptor de ppar-gama, e para tratar uma condição fisiológica em um paciente
BR0015307A (pt) Composto, composição, composição farmacêutica, métodos para tratar um distúrbio que é criado pela ou é dependente da disponibilidade diminuìda de serotonina, norepinefrina ou dopamina, e para inibir a absorção de norepinefrina sináptica, de serotonina sináptica e de dopamina sináptica em um paciente em necessidade destas, e, conjunto
BR9909277A (pt) Compostos com atividade em receptores muscarìnicos
BR9713914A (pt) Composto, uso do mesmo, composição farmacêutica, e processo para tratar um paciente sofrendo de um distúrbio que é susceptìvel a tratamento com um agonista da trombopoietina.
BRPI0411255A (pt) composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
MY132626A (en) CARBAZOLYL-SUBSTITUTED ETHANOLAMINES AS SELECTIVE ß-3 AGONISTS
BR9813524A (pt) Processos para tratamento de toxicidades associadas com a administração de um agente terapêutico a um mamìfero, para tratamento de toxicidades associadas com a exposição de um mamìfero à terapia de radiação, para tratamento de neuro- ou nefrodistúrbios em um humano, e, para tratamento de distúrbios e sintomas clìnicos associados com diabetes do tipo i ou do tipo ii em um humano
MX9802130A (es) Agonistas adrenergicos beta3 selectivos.
BR0315981A (pt) Composições para tratamento de tecidos que contêm diferentes silicones, processo para a sua preparação e método para a sua utilização
BR9808953A (pt) Composto, processo para tratar um distúrbio mediado pela ciclooxigenase-2 em um paciente, e, composição farmacêutica
BR9709427A (pt) Oxa ácidos e compostos relacionados para tratamento de condições da pele
ATE322283T1 (de) Transdermale verwendung von sekretin zur behandlung von autismus
BR9708747A (pt) Oxa diácidos e compostos relacionados para o tratamento de condições da pele
BR9813973A (pt) Composto, processo para prepará-lo, uso do mesmo, composição farmacêutica, e, processo para o tratamento de um paciente sofrendo de uma condição.
BR0317891A (pt) Tratamento de ferimentos de pele usando polienilfosfatidil colina e alcanolaminas
BR0206514A (pt) Composto, método de tratamento de um ser humano ou animal que sofre de enxaqueca, uso do composto, composição farmacêutica, e, processo para preparar um composto
BR0211400A (pt) Tratamento de distrofia muscular com células de sangue do cordão
BR9713921A (pt) Composto, composição farmacêutica, processo para tógico capaz de ser modulado através da inibição do fator xa
BR9805297A (pt) Derivados de 1,3,8-triazaspiro (4,5) decan-4on.
BR9610481A (pt) Agonistas adrenérgicos beta seletivos
ATE174508T1 (de) Verwendung von bis (amidinobenzidazolen) zur herstellung eines medikamentes für die hemmung der retroviral integrase
BR0011578A (pt) Utilização do s-enantiÈmero de citalopram para tratamento de distúrbio de ansiedade geral ou ataques de pânico
ATE199829T1 (de) Meta substituierte arylalkylamine und therapeutische und diagnostische verwendung davon
KR900014389A (ko) 아데노신 수용체 선택성 약제
BR9712503A (pt) Derivados anticonvulsivos úteis no tratamento de dor neuropática

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]